The estimated Net Worth of Gilbert S Omenn is at least $509 Tysiąc dollars as of 13 December 2021. Gilbert Omenn owns over 16,000 units of Galectin Therapeutics Inc stock worth over $212,805 and over the last 21 years he sold GALT stock worth over $116,607. In addition, he makes $179,098 as Independent Director at Galectin Therapeutics Inc.
Gilbert has made over 11 trades of the Galectin Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 16,000 units of GALT stock worth $18,880 on 13 December 2021.
The largest trade he's ever made was exercising 26,000 units of Galectin Therapeutics Inc stock on 26 November 2012 worth over $1,499,680. On average, Gilbert trades about 2,237 units every 95 days since 2003. As of 13 December 2021 he still owns at least 77,666 units of Galectin Therapeutics Inc stock.
You can see the complete history of Gilbert Omenn stock trades at the bottom of the page.
Dr. Gilbert S. Omenn M.D. Ph.D. serves as Independent Director of the Company since September 23 2014, served on the board of directors of Amgen Inc. for 27 years and of Rohm & Haas Company for 22 years. He currently serves on the boards of Oncofusion Therapeutics and MedsynBio LLC of Ann Arbor, MI. Dr. Omenn is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health and Director of the university-wide Center for Computational Medicine and Bioinformatics at the University of Michigan. Dr. Omenn served as executive vice president for medical affairs and as chief executive officer of the University of Michigan Health System from 1997 to 2002. Prior, he was dean of the School of Public Health and Community Medicine and professor of medicine and a Howard Hughes Medical Institute investigator at the University of Washington and Member of the Fred Hutchinson Cancer Research Center. Earlier he was Associate Director of the White House Office of Science and Technology Policy and of the Office of Management and Budget. He is the author of 600 research papers and scientific reviews and author/editor of 18 books. Dr. Omenn received his B.A. summa cum laude from Princeton University, M.D. magna cum laude from Harvard Medical School, and Ph.D. in genetics from the University of Washington.
As the Independent Director of Galectin Therapeutics Inc, the total compensation of Gilbert Omenn at Galectin Therapeutics Inc is $179,098. There are 9 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.
Gilbert Omenn is 79, he's been the Independent Director of Galectin Therapeutics Inc since 2014. There are no older and 19 younger executives at Galectin Therapeutics Inc.
Gilbert's mailing address filed with the SEC is C/O AMESITE INC., 607 SHELBY STREET, SUITE 700 PMB 214, DETROIT, MI, 48226.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr oraz Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: